Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Tulavi Therapeutics, Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units, showing no concentration in the personnel or units reviewing the applications. ATKINSON, JOSHUA ALEXANDER is the busiest examiner with 1 pending office action, which is 1 of the 2 pending office actions for the company. This indicates a decentralized prosecution pipeline.
The presence of 2 distinct examiners in 2 distinct art units for only 2 pending office actions requires the company to manage two separate administrative tracks. This structure suggests that the pending applications may target different biological or pharmaceutical classifications. Practitioners should prepare for independent reviews, as the 2 pending office actions are not consolidated under 1 distinct examiner or within 1 distinct art unit, necessitating a tailored approach for each matter. The involvement of 2 distinct examiners suggests a diverse range of technical subject matter within the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ATKINSON, JOSHUA ALEXANDER | 1 | 51.8% | +27.5% |
| HAGOPIAN, CASEY SHEA | 1 | 54.3% | +33.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17863251 | METHODS AND DEVICES FOR NERVE REGENERATION | HAGOPIAN, CASEY SHEA | 23d overdue |
| 18477383 | METHODS AND COMPOSITIONS FOR THE ABLATION OF NERVES | ATKINSON, JOSHUA ALEXANDER | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18477383 | METHODS AND COMPOSITIONS FOR THE ABLATION OF NERVES | ATKINSON, JOSHUA ALEXANDER | 1612 | §103§112DP | Final Rejection | — | Pending | Sep 28, 2023 |
| 17863251 | METHODS AND DEVICES FOR NERVE REGENERATION | HAGOPIAN, CASEY SHEA | 1617 | §103DP | Non-Final OA | 23d overdue | Pending | Jul 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTulavi Therapeutics, Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Joshua Alexander Atkinson has the most, with 1 of Tulavi Therapeutics, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
